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We described the demographics, cancer subtypes, comorbidities, and outcomes of patients 3 
with a history of cancer and COVID-19. Secondly, we compared patients hospitalized with 4 
COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. 5 
Methods 6 
We conducted a cohort study using eight routinely-collected healthcare databases from Spain 7 
and the US, standardized to the Observational Medical Outcome Partnership common data 8 
model. Three cohorts of patients with a history of cancer were included: i) diagnosed with 9 
COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-10 
2018. Patients were followed from index date to 30 days or death. We reported 11 
demographics, cancer subtypes, comorbidities, and 30-day outcomes. 12 
Results 13 
We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, 14 
respectively. Prostate and breast cancers were the most frequent cancers (range: 5-19% and 1-15 
14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, 16 
with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the 17 
diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. 18 
Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and 19 
hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=67,743) 20 
had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence 21 
of adverse events.  22 
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Conclusions 1 
Patients with a history of cancer and COVID-19 had multiple comorbidities and a high 2 
occurrence of COVID-19-related events. Hematological malignancies were frequent. 3 
Impact 4 
This study provides epidemiologic characteristics that can inform clinical care and etiological 5 
studies.  6 
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Introduction 1 
Shortly after the emergence of the coronavirus disease 2019 (COVID-19), patients with 2 
cancer were reported to be a high-risk population for COVID-19.(1,2) These patients have an 3 
increased susceptibility to infections as a result of their immunosuppressed state, caused by 4 
the cancer itself, certain types of chemo- or immunotherapy, or surgery and a higher exposure 5 
to healthcare-associated infections.(3)  In addition, patients with cancer are often older and 6 
have additional comorbidities, which might increase their risk of worse COVID-19 7 
outcomes.(4) 8 
Prior studies assessing COVID-19-related risks in the cancer population have demonstrated 9 
conflicting results. Some studies found that patients with cancer have an increased risk of 10 
COVID-19-related hospitalization, admission to intensive care units, and mortality compared 11 
to patients without cancer,(1,2,4,5)
 
whereas others did not.(6,7) These studies included a 12 
limited number of patients with cancer (mostly hospitalized) and used different definitions for 13 
cancer (e.g., active cancer, history of cancer), which limit their generalizability. Furthermore, 14 
they presented results for models adjusted by (different) arbitrary covariates, without a 15 
theoretical framework of confounding variables, which limits the interpretation for 16 
descriptive and causal inference purposes.(8,9) 17 
Given that COVID-19 is a novel disease, large descriptive studies are needed to inform 18 
public health strategies and clinical care, as well as to provide the groundwork for etiological 19 
studies. In addition, large studies with detailed information of medical conditions and health 20 
outcomes, such as thromboembolic events, in patients with cancer and COVID-19 are lacking 21 
to date. To fill that gap, we described the demographics, cancer subtypes, comorbidities and 22 
outcomes of patients with a history of cancer and COVID-19. In addition, we compared 23 
patients with a history of cancer hospitalized with COVID-19 to i) patients with a history of 24 
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cancer diagnosed with COVID-19; and ii) patients with a history of cancer hospitalized with 1 
seasonal influenza (2017-2018) as a benchmark. 2 
 3 
Materials and methods 4 
Study design and setting 5 
This multinational cohort study was part of the CHARYBDIS (Characterizing Health 6 
Associated Risks, and Your Baseline Disease In SARS-COV-2) project, designed by the 7 
Observational Health Data Sciences and Informatics (OHDSI) community. CHARYBDIS is 8 
a large-scale study aiming to characterize individuals with COVID-19 using routinely-9 
collected healthcare data (protocol available at https://www.ohdsi.org/wp-10 
content/uploads/2020/07/Protocol_COVID-19-Charybdis-Characterisation_V5.docx). 11 
Twenty-two databases standardized to the Observational Medical Outcomes Partnership 12 
(OMOP) Common Data Model (CDM)(10) have contributed to CHARYBDIS to date. The 13 
OHDSI network maintains the OMOP-CDM, and its members have developed a wide range 14 
of tools to facilitate analyses of such mapped data.(11) Results for this sub-study were 15 
extracted from the overarching result set on January 29
th
 2021.  16 
We included those databases reporting on at least 140 subjects with a history of cancer 17 
diagnosed and/or hospitalized with COVID-19. This cut-off was established to estimate the 18 
prevalence of conditions affecting 10% of the study population with a confidence interval 19 
(CI) width of +/- 5%. The selection process of databases is depicted in Supplementary Figure 20 
S1. Eight databases from Spain and the United States (US) were included in this study.  21 
Spanish data came from the SIDIAP database, a primary care database from Catalonia, a 22 
northeastern region in Spain.(12) Data from the US included Electronic Health Records 23 
(EHR) from the hospital setting: CU-AMC-HDC (Colorado), CUIMC (New York), Optum-24 
on July 19, 2021. © 2021 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
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11 
EHR (national),(13) STARR-OMOP (California), VA-OMOP (national, including mostly 1 
veterans with 93% males); and claims data: HealthVerity and IQVIA-OpenClaims (both 2 
national). A description of each database is provided in Supplementary Table S1. SIDIAP 3 
and CUIMC included patients with COVID-19 identified from March to May 2020, 4 
HealthVerity, and STARR-OMOP spanned to June 2020, CU-AMC-HDC to July 2020, VA-5 
OMOP to September 2020, and IQVIA-OpenClaims and Optum-EHR to October 2020. 6 
 7 
Study participants  8 
We included three non-mutually exclusive cohorts of patients with a history of cancer: i) 9 
diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with 10 
seasonal influenza in 2017-2018.  11 
We included all patients (regardless of age) with at least one year of observation time 12 
available prior to index date (i.e., date of start of the cohort). Patients with a history of cancer 13 
were defined as those having a record of any malignant neoplasm excluding non-melanoma 14 
skin cancer prior to index date. Patients diagnosed with COVID-19 were those having a 15 
clinical diagnosis and/or a positive severe acute respiratory syndrome coronavirus 2 (SARS-16 
CoV-2) test documented in outpatient or inpatient records. Patients hospitalized with 17 
COVID-19 were those who had a hospitalization episode and a COVID-19 clinical diagnosis 18 
or positive SARS-CoV-2 test within a time window of 21 days prior to admission up to the 19 
end of their hospitalization. We chose this time window to include patients with a diagnosis 20 
prior to hospitalization and to allow for a record delay in diagnoses or test results. Similarly, 21 
patients hospitalized with seasonal influenza were those who had a hospitalization episode 22 
and a influenza clinical diagnosis or positive test result for influenza in 2017-2018.(14) The 23 
criteria to define patients with cancer history and COVID-19 and influenza cases can be 24 
found in Supplementary Table S2. 25 
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12 
Index date for the diagnosed cohort was the date of clinical diagnosis or the earliest test day 1 
registered within seven days of a first positive test, whichever occurred first. Index date for 2 
both hospitalized cohorts (COVID-19 and influenza) was the day of hospitalization. 3 
Therefore, although time windows are slightly different, both COVID-19 cohorts largely 4 
overlap, as most individuals in the hospitalized cohort are also included in the diagnosed 5 
cohort.  6 
All patients were followed from the index date to the earliest of either death, end of the 7 
observation period,(15) or 30 days.  8 
 9 
Patient characteristics and outcomes 10 
We identified over 15,000 baseline medical conditions based on the Systematized 11 
Nomenclature of Medicine (SNOMED) hierarchy, with all descendant codes included.(15)
 
In 12 
addition, we created specific definitions for comorbidities and outcomes of particular interest 13 
(available in Supplementary Table S2). To describe the frequency of cancer subtypes by 14 
topographical location (henceforth, referred to as cancer types), we selected 26 cancer types 15 
based on the most prevalent cancers in both countries(16) The codes used to identify each 16 
cancer type are available in Supplementary Table S3. Of note, although we required all 17 
subjects in our study to have at least one year of prior history available, all the conditions 18 
recorded at any time prior to the index date (including the day prior) were reported. 19 
We report here sex, age, race, antineoplastic and immunomodulating treatment received the 20 
month and year prior to index date, and key comorbidities. The only information available for 21 
race was the proportion of African American patients, which was reported in four databases 22 
(CU-AMC-HDC, CUIMC, Optum-EHR and VA-OMOP). 23 
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The 30-day outcomes of interest in the diagnosed cohort were hospitalization and death (from 1 
all causes). In the hospitalized cohorts (COVID-19 and influenza), the outcomes of interest 2 
were acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), cardiovascular 3 
disease events, deep vein thrombosis, pulmonary embolism, sepsis, requirement of intensive 4 
services (identified by a recorded mechanical ventilation and/or a tracheostomy and/or 5 
extracorporeal membrane oxygenation procedure) and death (from all causes). SIDIAP only 6 
reported death and hospitalization, whereas CU-AMC-HDC did not report any outcome.   7 
 8 
Analysis 9 
Analysis was performed through a federated analysis approach.(15)
 
Following a pre-specified 10 
analysis plan, an analytical code for the whole CHARYBDIS study was developed and run 11 
locally in each site (code available at zenodo.org).(17) Individual-level data remained within 12 
host institutions, only aggregate results were provided to the research team. All the results are 13 
available for consultation on a regularly updated website as new databases and/or results are 14 
added (https://data.ohdsi.org/Covid19CharacterizationCharybdis/). 15 
We report results by cohort and database. Demographics, cancer types, comorbidities, and 16 
outcomes are reported as proportions along with 95% Confidence Intervals (CI). To calculate 17 
these proportions, a minimum count required of 5 individuals was established to minimize the 18 
risk of reidentification of patients. We also report the ranking of the 10 most common cancer 19 
types by frequency. In addition, we summarized the prevalence of all the baseline conditions 20 
retrieved in a Manhattan-style plot (a type of scatter plot used to represent large numbers of 21 
data points). 22 
To compare characteristics between study cohorts, we calculated standardized mean 23 
differences (SMD). SMD are independent of sample sizes and can be used to compare the 24 
prevalence of dichotomous variables between two groups. An |SMD|>0.1 indicates a 25 
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14 
meaningful difference in the prevalence of a given condition.(18)(19)
 
As this study was 1 
designed as a detailed descriptive study, statistical modelling was out of scope in the 2 
developed analytical packages. Therefore, differences across the groups compared should not 3 
be interpreted as causal effects.  4 
We used R version 3.6 for data visualization. All the data partners obtained Institutional 5 
Review Board (IRB) approval or exemption to conduct this study. 6 
 7 
Results 8 
Lifetime cancer prevalence 9 
Overall, we identified 3,067,116 patients diagnosed and 572,300 patients hospitalized with 10 
COVID-19.  The lifetime cancer prevalence range across databases was 4-25% in patients 11 
diagnosed; and 11-40% in patients hospitalized (Supplementary Table S4). Additionally, 12 
274,557 patients hospitalized with seasonal influenza in 2017-2018 were identified (lifetime 13 
cancer prevalence range: 18-39%).  14 
We included 366,050 patients diagnosed (Spain: 8,854; US: 357,196) and 119,597 patients 15 
hospitalized (Spain: 2,610; US: 116,987) with COVID-19 and cancer history; and 67,743 16 
patients hospitalized (all from the US) with seasonal influenza and cancer history. 17 
Demographics 18 
The distribution of demographics, comorbidities and outcomes of both COVID-19 cohorts 19 
can be found in Table 1 (95% CI of each condition available in Supplementary Table S5). In 20 
the diagnosed cohort, patients were more commonly female (range: 53-59%), aside from 21 
STARR-OMOP (47%) and VA-OMOP (7%). In contrast, in the hospitalized cohort, male 22 
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15 
slighty predominated in all databases (51-60%, VA-OMOP: 96%), aside from HealthVerity 1 
and Optum-EHR (50% in both). Patients were mainly aged above 65 years in both COVID-2 
19 cohorts but patients hospitalized were consistently older than those diagnosed 3 
(Supplementary Figure S2). In the few databases reporting race, the proportion of African 4 
American patients was higher in the hospitalized cohort (9-35%) than in the diagnosed cohort 5 
(6-29%).  6 
Cancer types 7 
For both COVID-19 cohorts, the frequency of each cancer type is reported in Supplementary 8 
Table S6. The top ten cancer types by frequency are reported in Table 2. In the diagnosed 9 
cohort, the most frequent cancers in four databases were breast (SIDIAP: 14.2%; CU-AMC-10 
HDC: 7.3%; Optum-EHR: 6.7%; and STARR-OMOP: 12.3%) and prostate cancer (CUIMC: 11 
6.1%; HealthVerity: 12.2%; IQVIA-OpenClaims: 6.4%; VA-OMOP: 18.1%). In all 12 
databases, non-Hodgkin’s lymphoma (NHL) was among the five most common cancers. 13 
Bladder, colorectal, leukemia, and lung cancer were among the ten most frequent in at least 7 14 
databases. 15 
In the hospitalized cohort, prostate cancer was the most frequent cancer in all databases 16 
(equally with NHL in CU-AMC-HDC, 6.4%); aside from Optum-EHR (second most 17 
frequent). NHL was among the three most frequent cancers in all databases aside from 18 
SIDIAP and STARR-OMOP, where NHL was the fifth most common. Leukemia, liver and 19 
lung cancer were also within the top ten in the majority of databases. We did not observe 20 
meaningful differences (i.e. |SMD|>0.1) when comparing cancer types between the diagnosed 21 
and the hospitalized cohorts (Supplementary Figure S3).  22 
Prior comorbidities 23 
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In both COVID-19 cohorts, the most common comorbidities were cardiometabolic 1 
conditions, which were more frequent in US databases (especially VA-OMOP) than in the 2 
Spanish SIDIAP database. For example, in the US the range of hypertension was 52-85% 3 
(Spain: 32%) among diagnosed and 58-93% (Spain: 33%) among hospitalized patients (Table 4 
1). The prevalence of all the prior conditions summarized is shown in Figure 1. Several 5 
comorbidities were more frequent among patients hospitalized compared to patients 6 
diagnosed (SMD>0.1): heart disease and chronic kidney disease (all databases except 7 
STARR-OMOP); hypertension and type 2 diabetes (all except SIDIAP and STARR-OMOP) 8 
(Figure 2).  9 
Thirty-day outcomes 10 
In the COVID-19 diagnosed cohort, hospitalization in the US databases ranged from 14% to 11 
32% (Spain: 25%) and occurrence of death from 2% to 10% (Spain: 14%). In the COVID-19 12 
hospitalized cohort, outcomes were heterogeneous across databases. ARDS (range 8-41%) 13 
was higher than 30% in 3 out of 6 databases (IQVIA-OpenClaims, Optum-EHR, VA-14 
OMOP). Sepsis (6-25%), cardiovascular disease events (7-21%) and AKI (10-16%) were also 15 
common. Thromboembolic events were less frequent (deep vein thrombosis: 2-5%; 16 
pulmonary embolism: 2-4%). Intensive services requirement ranged from 6% to 16%, 17 
whereas occurrence of death ranged from 6% to 26% in the US (Spain: 21%). 18 
Comparison of patients hospitalized with COVID-19 to those with influenza 19 
The characteristics of patients hospitalized with seasonal influenza and the frequency of each 20 
cancer type are reported in Supplementary Tables S7 and S8, respectively. Aside from VA-21 
OMOP (96% male), the proportion of males ranged from 45% to 53%, and the majority of 22 
patients clustered around the ages of 60 to 85 years old (Supplementary Figure S4). The 23 
proportion of African American patients was lower in the Influenza cohort than in the 24 
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hospitalized COVID-19 cohort (Optum-EHR: 10% vs 14%; VA-OMOP: 17% vs 35%). 1 
When comparing the frequency of cancer types between COVID-19 and influenza patients, 2 
we did not observe consistent differences across databases (Supplementary Figure S5). The 3 
distribution of comorbidities was similar in both groups, with few exceptions (Figure 3A). 4 
For example, COPD was more common among patients with influenza in CU-AMC-HDC, 5 
Optum-EHR and VA-OMOP (Figure 4A).  Aside from CUIMC, outcomes were slighty more 6 
frequent in patients with COVID-19 in all databases. ARDS and death were meaningfully 7 
more frequent in patients with COVID-19. ARDS ranged from 16% to 41% (COVID-19) vs 8 
14-30% (influenza), with SMD>0.2 in IQVIA-OpenClaims and Optum-EHR and SMD>0.1 9 
in VA-OMOP. Occurrence of death was higher among COVID-19 patients compared to 10 
influenza patients in Optum-EHR and VA-OMOP: 6 vs 1% and 18% vs 6%, respectively 11 
(SMD>0.2) (Figures 3B and 4B). 12 
 13 
Discussion 14 
In this multinational cohort study, we described the characteristics of 366,050 patients with a 15 
history of cancer and COVID-19, including outcomes rarely reported in this population (e.g. 16 
deep vein thrombosis, pulmonary embolism, or acute kidney injury). In both COVID-19 17 
cohorts, the most frequent cancer types were prostate cancer and breast cancer; hematological 18 
malignancies were also frequent. The proportion of patients that had received anticancer 19 
therapies the year or the month prior was similar in both cohorts. Comorbidities were 20 
common in both cohorts but were higher among those hospitalized. Occurence of death 21 
ranged from 2% to 14% among those diagnosed and from 6% to 26% among those 22 
hospitalized. When compared to patients with cancer history hospitalized with seasonal 23 
on July 19, 2021. © 2021 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 16, 2021; DOI: 10.1158/1055-9965.EPI-21-0266 
18 
influenza, patients hospitalized with COVID-19 had a similar distribution of age and 1 
comorbidities but had more severe outcomes.  2 
In the US, the lifetime cancer prevalence is 5%;(20) (data on the lifetime cancer prevalence in 3 
Spain is unavailable to our knowledge),(16) which is lower than our findings in COVID-19 4 
patients (range 4-25% in the diagnosed and 11-40% in the hospitalized cohort). Although 5 
comparisons are limited due to different cancer definitions, these prevalences are also higher 6 
than prior reports on COVID-19 patients at hospital settings, with cancer prevalences of 6-7 
11% in studies from Europe and the US.(21–24) A Danish study, however, found a lifetime 8 
cancer prevalence among patients hospitalized with COVID-19 of 17%, in line with our 9 
results.(6)  10 
The most lifetime-prevalent cancer types in the US are prostate and breast cancer.(20) These 11 
cancer types were also those more frequent in our COVID-19 cohorts. However, 12 
hematological malignancies were more frequent than expected in all our cohorts. For 13 
example, in the COVID-19 hospitalized cohort, NHL, leukemia and multiple myeloma were 14 
among the third, fifth, and tenth most common cancers, respectively. However, in the US 15 
cancer survivors’ population, NHL is only the fifth/sixth most frequent (men and women, 16 
respectively), whereas leukemia is the ninth in men. The overrepresentation of hematological 17 
malignancies in both COVID-19 cohorts raises questions on whether patients with these 18 
malignancies are more exposed or more vulnerable to SARS-CoV-2 infection, or both. Prior 19 
studies have reported a higher incidence of COVID-19 infection and,(25,26) more 20 
worryingly, an increased risk of COVID-19 complications in patients with hematological 21 
malignancies compared to patients with other cancers.(5,25) 22 
We also found that the proportions of patients that had received antineoplastic and 23 
immunomodulating agents the year or the month prior to the index date were similar in both 24 
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the diagnosed and the hospitalized cohorts. Although this suggests that recent cancer 1 
therapies might not be associated with increased COVID-19 severity, this finding must be 2 
interpreted with caution due to the overlap between cohorts. However, two studies including 3 
over 800 and 900 patients with cancer (from the UK Coronavirus Cancer Monitoring Project 4 
(UKCCMP) and the COVID-19 and Cancer Consortium (CCC19), respectively) found no 5 
association between cancer therapies and increased COVID-19-related mortality. (4) (27) 6 
As expected, patients with cancer history were older and had more comorbidities than overall 7 
COVID-19 cases. In a meta-analysis comprising 12,149 COVID-19 cases (mostly 8 
hospitalized), hypertension (23%), heart failure (20%), and diabetes (12%) were the most 9 
common comorbidities.(28) These numbers are substantially lower than our findings. 10 
Compared to studies describing cancer patients, we also found higher prevalences of 11 
comorbidities. For example, chronic kidney disease (range 20-44%), diabetes (24-59%) and 12 
obesity (26-60%) were higher in our hospitalized cohort than in a study including COVID-19 13 
inpatients with a history of solid cancer (16%, 22% and 10% had chronic kidney disease, 14 
diabetes and obesity, respectively).(22) In addition, heart disease, chronic kidney disease and 15 
type 2 diabetes were meaningfully higher among those hospitalized compared to those 16 
diagnosed. These conditions have been previously reported as potential risk factors for 17 
hospitalization, increased severity and mortality among COVID-19 cases.(29) Comorbidities 18 
should be taken into consideration when designing future studies assessing the effect of 19 
cancer on COVID-19-related health outcomes, as failing to adjust for some comorbidities or 20 
adjusting for others (over-adjustment) could lead to confounding and/or selection bias. 21 
In June 2020, the case-fatality ratio among confirmed COVID-19 cases was 11% in Spain 22 
and 5% in the US,(30) which is lower than the all-cause mortality observed in both cohorts in 23 
SIDIAP, CUIMC and VA-OMOP. Undoubtedly, increased age and underlying comorbidities 24 
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play a substantial role in COVID-19 related mortality among these patients. However, 1 
mortality was remarkably lower in the database including cases as of October 2020, Optum-2 
EHR (2% in patients diagnosed, 6% in patients hospitalized). This suggests that studies from 3 
the beginning of the pandemic, when testing was limited, might have overestimated mortality 4 
rates in COVID-19 patients, including those with cancer. For instance, a meta-analysis 5 
including studies prior to July 2020, with data over 18,000 cancer patients with COVID-19 6 
(mostly inpatients), reported a pooled case mortality rate of 25.6% (95% CI: 22.0-29.5%), 7 
(31) which is in line with our results in the hospitalized cohort in CUIMC (26%) and VA-8 
OMOP (18%) but higher than results in Optum-EHR. 9 
Finally, we compared patients with cancer history hospitalized with COVID-19 to those with 10 
seasonal influenza as a benchmark. We previously showed that COVID-19 patients are more 11 
often male, younger and less likely to have respiratory and cardiovascular diseases than 12 
influenza patients.(14) Interestingly, COVID-19 and influenza patients with a history of 13 
cancer had a similar sex and age distribution and were of comparable health status. Despite 14 
this similarity, patients with cancer history and COVID-19 had a higher occurrence of 15 
adverse outcomes than those with influenza. 16 
This study has several strengths, such as its large size. We have reported in a publicly 17 
available website more than 10,000 characteristics from over 300,000 and 100,000 patients 18 
diagnosed and hospitalized with history of cancer and COVID-19, respectively, using eight 19 
different databases. The diverse healthcare settings and populations described, together with 20 
our multinational approach, increase the generalizability of our findings. Further, we expect 21 
that more databases from additional countries will provide sufficient data on the cancer 22 
population as the pandemic evolves. By including only individuals with at least one year of 23 
observation time available, we have comprehensively captured baseline comorbidities, which 24 
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could explain the higher prevalence of comorbidities in our cohorts. In addition, we ensured 1 
confidentiality throughout the study using a federated analysis approach. Finally, for the 2 
purposes of transparency and reproducibility, our methods, tools, and results are all publicly 3 
available. 4 
However, this study also has limitations. First, we were not able to provide detailed cancer 5 
information, such as year of cancer diagnosis, nor identify patients with active cancer 6 
treatment; although we had information on the use of antineoplastic agents during the year 7 
and month prior to the index date. Second, by including patients with a clinical COVID-19 8 
diagnosis we might have incurred some false positives. However, we used a broad COVID-9 
19 definition to reduce selection bias due to testing restrictions during the first months of the 10 
pandemic, (32) as well as (hypothetical) differential patterns in testing between patients with 11 
cancer vs patients without cancer. Additionally, we did not have information on 12 
socioeconomic status, ethnicity, nor race in most databases. We also lacked information on 13 
the cause of death and reported instead all-cause death. Third, the overlap between the 14 
diagnosed and hospitalized COVID-19 cohorts might have masked some differences in the 15 
prevalence of comorbidities between cohorts. Moreover, some patients might be included in 16 
more than one database (e.g in a hospital-based and claims-based database from the US). 17 
Unfortunately, we were unable to determine the degree of overlap across data sources 18 
because patient-level data was not shared for confidentiality purposes. Fourth, the differences 19 
found in the COVID-19/seasonal influenza comparison may have been influenced by 20 
temporal changes in clinical practice standards and coding. Further, the influenza vaccine 21 
likely contributed to the low frequency of adverse events among influenza patients. Fifth, the 22 
use of routinely-collected data could have led to an underestimation of the lifetime cancer 23 
prevalence, cancer types, comorbidities, and outcomes due to incomplete reporting. Finally, 24 
our findings were heterogenous across data sources. Heterogeneity is a known phenomenon 25 
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when using real-world data that reflects the existence of different coding practices, 1 
observation period, healthcare settings and populations. While the interpretation of 2 
heterogeneous results is challenging, these also provide valuable insights into the 3 
particularities of each setting. Yet, despite this heterogeneity, we found consistent patterns 4 
when comparing characteristics across cohorts, which lends credence to our results.  5 
 6 
This in-depth characterization revealed that COVID-19 patients with a history of cancer are 7 
mostly aged above 65 years old and have multiple comorbidities that may explain the high 8 
frequency of severe COVID-19 outcomes in this population. In addition, we found that 9 
hematological malignancies were more frequent than expected. These findings are 10 
foundational for guiding future studies and highlight the importance of protecting patients 11 
with cancer while guaranteeing cancer care continuity during the pandemic.   12 
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Table 1. Demographics, comorbidities and outcomes among patients with a history of cancer diagnosed and hospitalized with COVID-19 3 
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Sex                 
Female 53.9 53.0 54.7 53.7 55.1 58.6 47.0 7.1 39.7 46.8 46.3 50.1 48.7 50.3 41.8 3.6 
Male 46.1 47.0 45.3 46.3 44.9 41.4 53.0 92.9 60.3 53.2 53.7 49.9 51.3 49.7 58.2 96.4 
Race, African 
American 





                
The month prior 10.9 22.5 12.3 5.4 9.8 6.3 18.8 12.0 10.8 28.3 14.6 5.9 10.7 10.9 18.9 14.2 
The year prior 13.6 35.1 24.6 20.3 18.0 16.3 31.9 21.5 13.7 37.7 26.0 18.6 19.9 20.7 29.9 24.1 
Comorbidities                 
Asthma 4.7 15.4 20.5 9.9 17.2 20.3 14.3 10.8 3.9 12.1 22.8 10.0 16.3 15.8 16.4 9.9 
COPD 33.7 23.7 19.8 17.3 26.8 18.4 11.9 43.3 41.5 29.4 28.2 31.4 34.8 28.6 11.1 53.2 
Type 2 diabetes 17.8 26.9 38.0 31.7 47.5 29.9 22.0 50.3 22.5 36.2 55.1 43.0 56.9 40.5 23.8 58.7 
Hyperlipidemia 22.8 38.7 30.8 40.1 38.4 44.7 38.7 58.8 24.6 42.3 38.0 48.4 41.5 49.1 44.3 61.2 
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30 
Obesity 41.8 49.3 52.8 21.8 35.5 60.4 40.0 52.7 47.8 52.1 57.0 25.7 38.8 60.4 39.8 53.4 
Heart disease 34.3 50.0 62.8 39.9 68.1 51.1 40.8 71.4 41.6 59.2 76.5 60.9 78.6 63.9 45.5 79.1 
Hypertension 33.2 60.2 70.0 58.1 80.8 61.3 52.4 86.7 37.3 69.4 83.1 74.4 89.4 73.3 58.2 92.8 
Anxiety 24.2 19.1 12.2 13.5 13.5 18.6 16.6 31.1 19.3 18.1 10.7 19.4 14.2 18.2 18.9 30.1 
Dementia 10.7 5.8 11.0 7.1 18.3 6.3 1.7 14.3 7.2 7.5 21.2 15.8 21.5 10.8 - 23.7 
Depression 7.2 9.2 14.8 2.7 12.3 10.9 10.4 21.1 5.7 9.1 20.0 4.9 12.7 9.6 12.7 19.1 
Anemia 19.6 22.1 19.3 24.8 24.8 18.0 24.7 25.8 20.0 35.1 25.0 40.9 33.3 29.1 32.0 36.7 
Autoimmune 
condition 
10.4 19.9 30.8 13.0 32.0 18.3 14.6 30.3 11.2 20.0 38.1 17.8 36.2 20.8 11.9 35.4 
Chronic kidney 
disease 
19.4 23.8 27.4 18.4 31.7 27.9 18.0 34.1 23.6 34.0 40.8 36.0 44.1 39.2 20.1 44.3 
Chronic liver 
disease 
1.9 3.2 3.6 2.2 2.0 2.4 7.3 6.1 1.8 4.9 5.0 4.0 3.0 3.5 4.9 8.8 
Outcomes                 
Death 14.4 - 10.4 - - 1.7 - 7.6 21.4 - 26.2 - - 5.5 - 18.1 




NA NA NA NA NA NA NA NA - - -  6.3 8.7 13.0 5.7 16.0 
ARDS during 
hospitalization 
NA NA NA NA NA NA NA NA - - 15.9 26.5 33.3 41.8 8.2 41.2 
Cardiovascular 
disease events 




NA NA NA NA NA NA NA NA - - 2.1 3.0 2.4 4.0 - 4.8 
Pulmonary NA NA NA NA NA NA NA NA - - 2.7 2.1 2.1 3.5 - 4.0 
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NA NA NA NA NA NA NA NA - - 16.0 11.4 9.6 16.6 11.9 14.4 
Sepsis during 
hospitalization 
NA NA NA NA NA NA NA NA - - 6.1 17.7 18.4 25.0 9.8 20.5 
 1 
Notes: - indicates data not available or below the minimum cell count required (5 individuals), NA indicates not applicable. 2 
Abbreviations: COVID-19: Coronavirus disease 2019; COPD: Chronic Obstructive Pulmonary Disease; ARDS: Acute Respiratory Distress Syndrome; AKI: Acute Kidney 3 
Injury; SIDIAP: Information System for Research in Primary Care; CU-AMC-HDC: Colorado University Anschutz Medical Campus Health Data Compass; CUIMC: 4 
Columbia University Irving Medical Center; STARR-OMOP: Stanford Medicine Research Data Repository; VA-OMOP: Department of Veterans Affairs  5 
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Table 2. Top 10 cancer types among patients with a history of cancer diagnosed and hospitalized with COVID-19 1 
 2 
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Notes: - indicates data not available. A single individual can have multiple cancer types records. 2 
Abbreviations: COVID-19: Coronavirus disease 2019; SIDIAP: Information System for Research in Primary Care; CU-AMC-HDC: Colorado University Anschutz Medical 3 
Campus Health Data Compass; CUIMC: Columbia University Irving Medical Center; STARR-OMOP: Stanford Medicine Research Data Repository; VA-OMOP: 4 
Department of Veterans Affairs; NHL: Non-Hodgkin's lymphoma; LOCP: Lip, oral cavity and pharynx 5 
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Figure legends  1 
 2 
Figure 1. Prevalence of baseline conditions among patients with a history of cancer 3 
diagnosed and hospitalized with COVID-19. 4 
Each dot represents the prevalence of one baseline condition, with the color indicating the 5 
type of condition (i.e. the group, for example blood disease, etc.). Conditions are represented 6 
by cohort and database along the X-axis, whereas the prevalence (in %) is displayed on the 7 
Y-axis.  8 
 9 
Notes: only conditions meeting the minimum count requirement (5 individuals) are shown. N of conditions 10 
means the total number of conditions depicted (by cohort and database).   11 
Abbreviations: COVID-19: Coronavirus disease 2019; SIDIAP: Information System for Research in Primary 12 
Care; CU-AMC-HDC: Colorado University Anschutz Medical Campus Health Data Compass; CUIMC: 13 
Columbia University Irving Medical Center; STARR-OMOP: Stanford Medicine Research Data Repository; 14 
VA-OMOP: Department of Veterans Affairs 15 
 16 
Figure 2. Standardized mean differences of selected baseline comorbidities between 17 
patients with cancer diagnosed and hospitalized with COVID-19.  18 
SMD<0 indicates that the prevalence was greater in patients diagnosed,  SMD>0 indicates 19 
that the prevalence was greater in patients hospitalized. 20 
 21 
Notes: Comorbidities ordered according to SMD descending values in the largest database (IQVIA-22 
OpenClaims). Black-dotted lines indicate a |SMD| of 0.1. SMD calculated for comorbidities meeting the 23 
minimum count required (5 individuals) in each database and cohort.  24 
Abbreviations: COVID-19: Coronavirus disease 2019; COPD: Chronic Obstructive Pulmonary Disease; 25 
ARDS: Acute Respiratory Distress Syndrome; AKI: Acute Kidney Injury; CU-AMC-HDC: Colorado University 26 
Anschutz Medical Campus Health Data Compass; CUIMC: Columbia University Irving Medical Center; 27 
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STARR-OMOP: Stanford Medicine Research Data Repository; VA-OMOP: Department of Veterans Affairs; 1 
SMD: Standardized Mean Difference 2 
 3 
Figure 3. Baseline comorbidities (A) and 30-day outcomes (B) among patients with 4 
history of cancer hospitalized with COVID-19 and with seasonal influenza 5 
 6 
Notes: Comorbidities and outcomes ordered according to descending values in the largest database (IQVIA-7 
OpenClaims). Comorbidities and outcomes are shown if meeting the minimum count required (5 individuals) in 8 
each database and cohort. Outcomes not shown due to data not available: all outcomes in CU-AMC-HDC, 9 
occurence of death  in CUIMC (influenza cohort) and IQVIA-OpenClaims, intensive services in CUIMC. 10 
Abbreviations: COVID-19: Coronavirus disease 2019; COPD: Chronic Obstructive Pulmonary Disease; 11 
ARDS: Acute Respiratory Distress Syndrome; AKI: Acute Kidney Injury; CU-AMC-HDC: Colorado University 12 
Anschutz Medical Campus Health Data Compass; CUIMC: Columbia University Irving Medical Center; 13 
STARR-OMOP: Stanford Medicine Research Data Repository; VA-OMOP: Department of Veterans Affairs 14 
 15 
Figure 4. Standardized mean differences of selected baseline comorbidities (A) and 30-16 
day outcomes (B) between patients with a history of cancer hospitalized with COVID-19 17 
and with seasonal influenza. 18 
SMD <0 indicates that the prevalence was greater in patients with seasonal influenza, 19 
SMD>0 indicates that the prevalence was greater in patients hospitalized. 20 
 21 
Notes: Comorbidities and outcomes ordered according to SMD descending values in the largest database 22 
(IQVIA-OpenClaims). Black-dotted lines indicate a |SMD| of 0.1. SMD calculated for comorbidities and 23 
outcomes meeting the minimum count required (5 individuals) in each database and cohort. Outcomes not 24 
shown due to data not available: all outcomes in CU-AMC-HDC, occurence of death in CUIMC and IQVIA-25 
OpenClaims, intensive services in CUIMC. 26 
Abbreviations: COVID-19: Coronavirus disease 2019; COPD: Chronic Obstructive Pulmonary Disease; 27 
ARDS: Acute Respiratory Distress Syndrome; AKI: Acute Kidney Injury; CU-AMC-HDC: Colorado University 28 
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Anschutz Medical Campus Health Data Compass; CUIMC: Columbia University Irving Medical Center; 1 
STARR-OMOP: Stanford Medicine Research Data Repository; VA-OMOP: Department of Veterans Affairs; 2 
SMD: Standardized Mean Difference 3 
 4 
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